title: New targets for drug discovery against malaria.
abstract: A mathematical model which predicts the intraerythrocytic stages of Plasmodium falciparum infection was developed using data from malaria-infected mice. Variables selected accounted for levels of healthy red blood cells, merozoite (Plasmodium asexual phase) infected red blood cells, gametocyte (Plasmodium sexual phase) infected red blood cells and a phenomenological variable which accounts for the mean activity of the immune system of the host. The model built was able to reproduce the behavior of three different scenarios of malaria. It predicts the later dynamics of malaria-infected humans well after the first peak of parasitemia, the qualitative response of malaria-infected monkeys to vaccination and the changes observed in malaria-infected mice when they are treated with antimalarial drugs. The mathematical model was used to identify new targets to be focused on drug design. Optimization methodologies were applied to identify five targets for minimizing the parasite load; four of the targets thus identified have never before been taken into account in drug design. The potential targets include: 1) increasing the death rate of the gametocytes, 2) decreasing the invasion rate of the red blood cells by the merozoites, 3) increasing the transformation of merozoites into gametocytes, 4) decreasing the activation of the immune system by the gametocytes, and finally 5) a combination of the previous target with decreasing the recycling rate of the red blood cells. The first target is already used in current therapies, whereas the remainders are proposals for potential new targets. Furthermore, the combined target (the simultaneous decrease of the activation of IS by gRBC and the decrease of the influence of IS on the recycling of hRBC) is interesting, since this combination does not affect the parasite directly. Thus, it is not expected to generate selective pressure on the parasites, which means that it would not produce resistance in Plasmodium.
authors.affiliation: Departamento de Bioquímica y Biología Molecular, Universidad de La Laguna, San Cristóbal de La Laguna, Tenerife, Spain.
authors.forename: Guido
authors.initials: G
authors.lastname: Santos
authors.forename: Néstor V
authors.initials: NV
authors.lastname: Torres
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D015195:Drug Design; D055808:Drug Discovery; D004912:Erythrocytes / Q000187:drug effects / Q000469:parasitology; D005260:Female; D007107:Immune System / Q000469:parasitology; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000503:physiopathology; D052940:Merozoites / Q000502:physiology; D051379:Mice; D008962:Models, Theoretical; D018512:Parasitemia / Q000188:drug therapy; D010963:Plasmodium falciparum / Q000187:drug effects*
chemical_list: D000962:Antimalarials
references.citation: Science. 2010 Sep 3;329(5996):1153-4
references.pmid: 20813940
references.citation: Math Biosci. 2009 Jan;217(1):11-8
references.pmid: 18851981
references.citation: Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
references.pmid: 21701501
references.citation: Science. 1999 Jan 15;283(5400):381-7
references.pmid: 9888852
references.citation: Mol Biochem Parasitol. 2010 Aug;172(2):57-65
references.pmid: 20381542
references.citation: Trop Med Int Health. 2008 Jan;13(1):83-90
references.pmid: 18291006
references.citation: Infect Immun. 1996 Apr;64(4):1373-8
references.pmid: 8606103
references.citation: Math Biosci. 2009 Jan;217(1):1-10
references.pmid: 18835282
references.citation: J Cell Biol. 1978 Apr;77(1):72-82
references.pmid: 96121
references.citation: J Pharm Biomed Anal. 2002 Apr 1;28(1):13-22
references.pmid: 11861104
references.citation: J Biol Chem. 2010 May 7;285(19):14815-22
references.pmid: 20228060
references.citation: Acta Trop. 2011 May;118(2):71-9
references.pmid: 21439929
references.citation: J Biol Chem. 2009 Apr 3;284(14):9361-71
references.pmid: 19164290
references.citation: Malar J. 2012 Jan 09;11:11
references.pmid: 22230255
references.citation: Trends Parasitol. 2008 Dec;24(12):578-84
references.pmid: 18848497
references.citation: Lancet. 2012 May 26;379(9830):1960-6
references.pmid: 22484134
references.citation: Methods Enzymol. 2011;487:319-69
references.pmid: 21187230
references.citation: Indian J Exp Biol. 1991 Mar;29(3):284-5
references.pmid: 1874546
references.citation: Indian J Med Microbiol. 2011 Jul-Sep;29(3):243-8
references.pmid: 21860103
references.citation: Infect Drug Resist. 2010;3:87-94
references.pmid: 21694897
references.citation: Exp Gerontol. 2008 Aug;43(8):764-70
references.pmid: 18556166
references.citation: Infect Immun. 2005 Oct;73(10):6981-9
references.pmid: 16177378
references.citation: Nat Rev Drug Discov. 2010 Mar;9(3):203-14
references.pmid: 20168317
references.citation: Biochem J. 1998 Feb 1;329 ( Pt 3):477-87
references.pmid: 9445373
references.citation: Mol Biosyst. 2010 Apr;6(4):699-710
references.pmid: 20237648
references.citation: BMC Syst Biol. 2012 Jan 05;6:1
references.pmid: 22222070
references.citation: J Theor Biol. 2000 Jan 21;202(2):113-27
references.pmid: 10640432
references.citation: PLoS Pathog. 2012;8(6):e1002755
references.pmid: 22737069
references.citation: Trends Parasitol. 2011 Feb;27(2):91-8
references.pmid: 20843745
references.citation: Malar J. 2008 Jul 09;7:125
references.pmid: 18613962
references.citation: Int J Parasitol. 2006 Dec;36(14):1427-41
references.pmid: 17005183
references.citation: Infect Immun. 1998 Sep;66(9):4080-6
references.pmid: 9712751
references.citation: Bioinformatics. 2007 Sep 1;23(17):2281-9
references.pmid: 17586544
references.citation: Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):181-92
references.pmid: 18165491
references.citation: Int J Parasitol. 2009 Feb;39(3):347-54
references.pmid: 18755194
references.citation: Nat Rev Microbiol. 2006 Aug;4(8):621-8
references.pmid: 16845432
references.citation: Int J Parasitol. 2004 Dec;34(13-14):1413-29
references.pmid: 15582519
references.citation: J Infect Dis. 2006 Mar 1;193(5):731-40
references.pmid: 16453270